Medical therapy for polycystic liver disease

Abstract

Introduction Somatostatin analogues and rapamycin inhibitors are two classes of drugs available for the management of polycystic liver disease but their overall impact is not clearly established. This article systematically reviews the literature on the medical management of polycystic liver disease. The outcomes assessed include reduction in liver volume and the impact on quality of life. Methods The English language literature published between 1966 and August 2014 was reviewed from a MEDLINE®, PubMed, Embase™ and Cochrane Library search. Search terms included ‘polycystic’, ‘liver’, ‘sirolimus’, ‘everolimus’, ‘PCLD’, ‘somatostatin’, ‘octreotide’, ‘lanreotide’ and ‘rapamycin’. Both randomised trials and controlled studies were included. References of the articles retrieved were also searched to identify any further eligible publications. The studies included were appraised using the Jadad score. Results Seven studies were included in the final review. Five studies, of which three were randomised trials, investigated the role of somatostatin analogues and the results showed a mean reduction in liver volume ranging from 2.9% at six months to 4.95 ±6.77% at one year. Only one randomised study examined the influence of rapamycin inhibitors. This trial compared dual therapy with everolimus and octreotide versus octreotide monotherapy. Liver volume reduced by 3.5% and 3.8% in the control and intervention groups respectively but no statistical difference was found between the two groups (p=0.73). Two randomised trials investigating somatostatin analogues assessed quality of life using SF-36®. Only one subdomain score improved in one of the trials while two subdomain scores improved in the other with somatostatin analogue therapy. Conclusions Somatostatin analogues significantly reduce liver volumes after six months of therapy but have only a modest improvement on quality of life. Rapamycin inhibitors do not confer any additional advantage.

Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases

“…In this context, cAMP drives PKA-dependent cell proliferation and hypersecretion 93,94,103,107 . Somatostatin analogues are approved by the FDA for the treatment of individuals with PLD owing to their downregulation of cAMP levels in cystic cholangiocytes 62,63,108,109 . Moreover, new therapeutic strategies aimed at increasing intracellular Ca 2+ levels in cystic cholangiocytes are under investigation (for instance, ursodeoxycholic acid (UDCA) and transient receptor potential cation channel subfamily V (TRPV4) agonists) 70,110,111 .…”

Transarterial Embolization for Treatment of Symptomatic Polycystic Liver Disease

“…Severe symptoms such as abdominal pain, distention, and nausea can affect about 20% of patients who develop massive hepatomegaly with compression of the surrounding organs. [ 3 4 ] Conventional treatments for patients with symptomatic PLD include percutaneous cyst aspiration with or without injection of sclerosing solution, laparoscopic fenestration, open surgical cyst fenestration, or partial hepatectomy. However, despite these treatments, both cysts and symptoms tend to recur (cysts and symptoms would recur in spite of active treatment).…”

Clinical intervention studies of orofacial motricity: an analysis of the methodological quality of brazilian studies

“…The Jadad scale evaluates three aspects: randomization (randomness in the selection of the study sample and the reliability of this aspect), blinding (whether it is appropriate) and the losses to follow-up in the study. This scale is well accepted in the international literature and aims to measure the quality of clinical trials [11][12][13] . It contains five questions and evaluates the quality of the methodology used.…”